Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

NICE backs NHS use of Pfizer’s PARP inhibitor Talzenna in HER2-, BRCA+ advanced breast cancer, the first targeted therapy for these patients.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

“Men with metastatic castration-resistant prostate cancer are often faced with a poor prognosis and limited treatment options, and Talzenna in combination with Xtandi has redefined the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and ...

See which leaders are on the move across the pharma, biotech and medical marketing industries.

Pfizer Inc. is actively advancing its research portfolio with several ongoing clinical studies that could significantly impact its stock performance and market position. One of the notable studies ...